Histopathology and Molecular Genetics of Multiple Cysts and Microcystic (Serous) Adenomas of the Pancreas in von Hippel-Lindau Patients

Victoria H. Mohr,* Alexander O. Vortmeyer,† Zhengping Zhuang,‡ Steven K. Libutti,§ McClellan M. Walther,§ Peter L. Choyke,† Berton Zbar,‖ W. Marston Linehan,§ and Irina A. Lubensky*†

From the Laboratory of Pathology,* National Cancer Institute, Bethesda; the Surgical Neurology Branch,† National Institute of Neurological Disorders and Stroke, Bethesda; the Surgery Branch§ and Urologic Oncology Branch;§ National Cancer Institute, Bethesda; the Department of Radiology,‖ Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda; and the Laboratory of Immunobiology,§ National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland

Microcystic adenoma and cysts of the pancreas occur sporadically or as a part of von Hippel-Lindau (VHL) disease. The pathology of pancreatic cystic disease in VHL patients has not been well characterized. Furthermore, it is presently unknown whether the alteration of the VHL gene is responsible for the development of the entire spectrum of pancreatic serous cystic lesions. We performed a histopathological analysis of 21 cysts and 98 microcystic adenomas in nine VHL patients with a known germline mutation. In addition, PCR-amplified DNA from 27 pancreatic cystic lesions in three informative patients was studied for allelic deletions with polymorphic markers spanning the VHL gene locus. In all patients, pancreatic lesions were multiple: 21 benign serous cysts, 63 microcystic microcystic adenomas (size <0.4 cm), and 35 macroscopic microcystic adenomas (size >0.5 cm). The average number of lesions per patient was 2.1 benign cysts (range, 0–8), 7.7 (1–37) microscopic microcystic adenomas, and 3 (0–21) macroscopic microcystic adenomas. All lesions showed similar histology and contained prominent fibrous stroma, clear and/or amorphophilic, glycogen-rich epithelial cells, endothelial and smooth muscle cells. VHL deletions were detected in all types of pancreatic cystic lesions. The presence of VHL gene allelic deletions in the spectrum of multifocal pancreatic cystic lesions provides direct molecular evidence of their neoplastic nature and integral association with VHL disease. The histopathological and molecular data establish a serious cyst-microcystic adenoma continuum in the development of pancreatic cystic neoplasia in VHL disease. (Am J Pathol 2000, 157:1615–1621)

von Hippel-Lindau (VHL) disease is an autosomal dominant disorder in that affected individuals are predisposed to develop a variety of neoplasms in multiple target organs. The lesions are frequently multiple in a given organ and include hemangioblastoma of the central nervous system, retinal angioma, endolymphatic sac tumor, renal cell carcinoma (RCC), pheochromocytoma, and cysts of the kidneys and epididymis. Pancreatic neuroendocrine (islet cell) tumors are reported to occur with an incidence of 12 to 17% in VHL patients. However, the most common manifestations of pancreatic disease are benign serous cysts (BC) and a microcystic (serous) adenoma (MCA), which occur in 35 to 75% of VHL patients. MCA may also occur sporadically and is a benign tumor with cystic or solid architecture composed of cysts of various sizes lined by flattened or cuboidal glycogen-rich cells. The origin of this cell remains unclear, although previous histological and ultrastructural studies suggested derivation from a centroacinar cell or ductal cell. Although VHL-associated cystadenoma has been reported in medical and radiology literature, the histopathology of pancreatic cystic disease in VHL patients has not been well characterized.

The VHL tumor suppressor gene has been localized to the chromosome 3p25.5 and identified in 1993. The two-hit theory of Knudson predicts that in a familial cancer syndrome such as VHL disease, the genotype of each neoplasm is determined by the presence of the inherited allele with a germline mutation and by the wild-type allele loss through allelic deletion. Molecular genetic studies of VHL disease-associated neoplasms such as central nervous system hemangioblastoma, retinal angioma, renal cysts and RCC, pheochromocytoma, pancreatic neuroendocrine tumor, and endolymphatic sac tumor have demonstrated loss of heterozygosity (LOH) at the VHL gene region. Although VHL allelic deletions have been reported in VHL-related
MCA, it is presently unknown whether the alteration of the VHL gene is responsible for development of the entire spectrum of pancreatic serous cystic lesions in VHL patients.

Materials and Methods

Patients

Nine VHL patients (3 female, 6 male; mean age, 42 years; range, 29–71 years) with pancreatic cystic lesions were selected from the group of familial VHL patients followed on the Institutional Review Board-approved protocol at the National Cancer Institute of the National Institutes of Health (Table 1). Patients had a documented germline mutation in the VHL gene, and in two VHL patients (nos. 6 and 9), the VHL germline mutation was detected in a close relative. Most patients were clinically asymptomatic, and their pancreatic cystic lesions were discovered incidentally during VHL screening by computed tomography or magnetic resonance imaging (CT/MRI), histopathological evaluation of the pancreas adjacent to the surgically removed neuroendocrine (islet cell) tumor, or autopsy.

Tumors

Formalin-fixed, paraffin-embedded pancreatic tissue and 119 pancreatic cystic lesions were obtained from the files of the Laboratory of Pathology, National Cancer Institute. All lesions were examined grossly and microscopically. Lesions were evaluated on hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), PAS-diastase (PAS-D), and Masson’s trichrome stains. Immunohistochemistry stains for cytokeratins MAK 6 (1:2; Zymed, San Francisco, CA) and AE1/AE3 (1:300/1:100; Boehringer Mannheim, Indianapolis, IN), chromogranin A (1:1600; Boehringer Mannheim, Indianapolis, IN), CD31 (1:20), vimentin (1:40), and smooth muscle actin (SMA; 1:160; DAKO, Carpenteria, CA) were performed. Pancreatic lesions were arbitrarily classified based on architecture and size as i) single benign serous cyst (BC), ii) microscopic MCA (mMCA; <0.4 cm in size), or iii) macroscopic MCA (MMCA; >0.5 cm in size) (Table 1, Figure 1).

Microdissection

Formalin-fixed, paraffin-embedded 5-μm tissue sections on glass slides from 27 pancreatic cystic lesions in three patients were used for LOH analysis. A modified microdissection procedure was performed under direct light microscopic visualization using a 30 gauge needle as previously described. Cyst-lining epithelial cells were selectively procured for analysis. Because the endothelial cells were closely intermixed with the epithelial cells in pancreatic lesions under study, we were unable to completely exclude endothelial cells during microdissection and LOH analysis. Stromal and smooth muscle cells were not used for analysis. Control samples were obtained from the matched normal pancreatic exocrine and endocrine tissue on the same histological slide.

DNA Extraction

Procured cells were resuspended immediately in 10 to 20 μl of buffer containing Tris/HCl, pH 8.0, 10 mMol/L ethylenediamine tetra-acetic acid, pH 8.0, 1% Tween 20, and 0.1 mg/ml proteinase K, and were incubated at 37°C overnight. The mixture was boiled for 10 minutes to inactivate proteinase K, and 1.5 μl of this solution was used for the polymerase chain reaction (PCR) amplification of DNA.

LOH Analysis

Twenty-seven cystic lesions from three informative patients were analyzed for LOH with two microsatellite markers, D3S1110 and D3S1038 (Research Genetics, Table 1. Clinical, Histopathological and Genetic Data in Nine VHL Patients with Cystic Disease of the Pancreas

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age/sex</th>
<th>Procedure</th>
<th>BC no.</th>
<th>MMCA no.</th>
<th>mMCA no.</th>
<th>VHL germline mutation</th>
<th>LOH at 3p25.5</th>
<th>Other VHL tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>42/M</td>
<td>Distal pancr</td>
<td>3</td>
<td>6</td>
<td>0</td>
<td>nt 703, C to T, Gln to stop, exon 3</td>
<td>3 BC and 6 mMCA</td>
<td>h</td>
</tr>
<tr>
<td>2*</td>
<td>44/F</td>
<td>Distal pancr</td>
<td>8</td>
<td>21</td>
<td>37</td>
<td>nt 430, C to T, Pro to Ser, exon 1</td>
<td>1 BC, 2 mMCA and 4 mMCA</td>
<td>h, ra</td>
</tr>
<tr>
<td>3</td>
<td>31/M</td>
<td>Enucleation</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>Partial deletion</td>
<td>ND</td>
<td>h, ph, ra, rcc, rc, net</td>
</tr>
<tr>
<td>4*</td>
<td>34/M</td>
<td>Panc/duod</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td>Partial deletion</td>
<td>ND</td>
<td>h, ph, ra, rc, net</td>
</tr>
<tr>
<td>5</td>
<td>47/F</td>
<td>Total pancr</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>nt 712, C to T, Arg to Trp, exon 3</td>
<td>ND</td>
<td>h, ra, ph, rc</td>
</tr>
<tr>
<td>6</td>
<td>42/F</td>
<td>Total pancr</td>
<td>2</td>
<td>1</td>
<td>6</td>
<td>nt 393 del G, codon 137, exon 1, stop</td>
<td>ND</td>
<td>h, net</td>
</tr>
<tr>
<td>7</td>
<td>29/M</td>
<td>Partial pancr</td>
<td>6</td>
<td>0</td>
<td>9</td>
<td>nt 699 C to G, Cys to Trp, exon 3</td>
<td>ND</td>
<td>h, ra, ph, rcc, net</td>
</tr>
<tr>
<td>8</td>
<td>40/M</td>
<td>Autopsy</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>NA</td>
<td>ND</td>
<td>h, ph, rcc</td>
</tr>
<tr>
<td>9</td>
<td>71/M</td>
<td>Autopsy</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>nt 430, C to T, Pro to Ser, exon 1</td>
<td>ND</td>
<td>h, ra, ph, rcc, rc</td>
</tr>
</tbody>
</table>

F, female; M, male; pancr, pancreatectomy; panc/duod, pancreaticoduodenectomy (Whipple’s procedure); BC, single benign cyst; mMCA, microscopic microcystic adenoma; MMCA, macroscopic microcystic adenoma; h, hemangioblastoma; ra, retinal angioma; ph, pheochromocytoma; rcc, renal cell carcinoma; rc, renal cysts; net, pancreatic neuroendocrine tumor; NA, not available; ND, not done.

*DNA from patients used for LOH study.
Huntsville, AL), flanking the VHL gene on chromosome 3p25.5. For both microsatellite markers PCR was performed for 35 cycles: denaturing at 95°C for 1 minute, annealing at 55°C for 40 seconds, and extending at 72°C for 1 minute. For all primers, the final extension was continued for 10 minutes.

Each PCR sample contained 1.5 μl of template DNA as noted above, 10 pmol of each primer, 20 nmol each of dATP, dCTP, dGTP, and dTTP, 15 mmol/L MgCl2, 0.1 U of Taq DNA polymerase, 0.05 μl of [32P] dCTP (6000 Ci/mmol), and 1 μl of 10× buffer in a total volume of 10 μl. Labeled amplified DNA was mixed with an equal volume of formamide loading dye (95% formamide, 20 mmol/L EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol) and analyzed on a single-strand conformation polymorphism gel. The samples were denatured for 5 minutes at 95°C and loaded onto a gel consisting of 6% acrylamide (49:1 acrylamide:bis), 5% glycerol, and 0.6× TBE. Samples were electrophoresed at 8W at room temperature overnight. Gels were transferred to 3-mm Whatman paper and dried, and autoradiography was performed with Kodak X-OMAT film (Eastman Kodak, Rochester, NY). The complete absence or 70% decreased intensity of one allele on acrylamide gel was interpreted as LOH. Seventy percent decrease in intensity of the wild-type allele was used for LOH scoring in this study because contaminating endothelial cells could not be completely excluded during microdissection of the epithelial cells (Figure 4). Each result was reproduced 2–3 times.

**Results**

In all nine VHL patients, pancreatic cystic lesions were multiple. The lesions >0.4 cm in size were seen grossly as cysts, and, in cases of MCA, as a conglomerate of cysts ranging in size from 0.5 to 18 cm or subtotally replacing normal pancreatic parenchyma (Figure 2). We classified the lesions as follows: 21 BC in 5 patients (average number per patient 2.1; range, 0–8), 35 MMCA in 9 patients (average number per patient 3.0; range, 0–21), and 63 mMCA in 9 patients (average number per patient 7.7; range, 1–37) (Table 1). Histologically, MCA contained prominent fibrous stroma, and all lesions were surrounded by fibrous tissue (Figures 1 and 2). Occasionally entrapped islets of Langerhans were seen in fibrous stroma. All lesions were cystic and, rarely, solid in architecture. A predominant population of bland, cuboidal, and flattened serous epithelial cells with clear and/or amphophilic cytoplasm, lack of nuclear atypia, mitoses, or necrosis was present in all lesions. The cells were strongly positive for cytokeratins AE1/AE3 and MAK 6, and rich in intracytoplasmic glycogen on PAS/PAS-D stains (Figures 2 and 3). The second population of numerous endothelial cells forming capillaries and closely intermixed with epithelial cells was consistently seen on H&E and CD31 stains in all BC, mMCA, and MMCA in the study (Figures 1 and 3). Furthermore, immunohistochemistry revealed the third cell type in all lesions: a smooth muscle cell, which was strongly positive for vimentin and
Figure 2. Gross pathology and histochemistry of VHL pancreatic cystic lesions. A: Multifocal cystic and solid pancreatic lesions. B: Subtotal replacement of pancreatic parenchyma by cystic disease. C: Prominent glycogen in the epithelial cells (PAS stain) (×630). D: Prominent stromal fibrosis (Masson's trichrome stain) (×400).

Figure 3. H&E and immunohistochemical stains in a VHL pancreatic MCA. A: Epithelial and endothelial cells (H&E). B: Positive cytokeratin MAK6 stain in the epithelial cells. C: Positive CD31 stain in the endothelial cells. D: Positive SMA stain in the smooth muscle cells. (all ×630).
SMA (Figure 3). Electron microscopy performed on five representative lesions confirmed the presence of the above three cell types and didn’t demonstrate dense core endocrine granules. Surrounding pancreas was normal or, in cases of large MCA, showed compression of the exocrine and endocrine tissue.

DNA from 27 microdissected BC, mMCA, MMCA, and normal exocrine and endocrine pancreas was analyzed for LOH at the VHL gene locus using polymorphic markers D3S1110 and D3S1038 in three patients with known germline mutations (Table 1; patients 1, 2, and 4). These patients were informative for both markers; ie, their normal DNA showed two different alleles (heterozygosity). In three patients analyzed, LOH for both markers was detected in 24 out of 27 different cystic lesions (Figure 4). LOH of the same wild-type allele was consistently seen in multiple lesions from an individual patient. Failure to detect LOH in two MMCA and one mMCA of patient 2 (Figure 4) could be due to contaminating endothelial cells.

Discussion

This report is the first detailed morphological and molecular genetic description of pancreatic cystic disease in VHL patients. We identified a spectrum of multiple pancreatic cystic lesions located throughout the pancreas and subdivided them by size and architecture into BC, mMCA, and MMCA. Our data demonstrate that all three subtypes of cystic lesions represent architectural and histological variants of the same molecular genetic process rather than three separate entities. Histologically, all lesions demonstrated a mixture of clear and/or amphotelic, glycogen-rich epithelial cells, endothelial cells, and smooth muscle cells, and showed prominent fibrosis. On the molecular level, the epithelial cells in 24 different lesions exhibited loss of the wild-type allele at the VHL gene locus, providing evidence of the neoplastic nature and close relationship of pancreatic serous cysts and MCA and establishing them as an integral part of VHL disease.

Clinically, pancreatic cystic lesions in VHL are benign and follow an indolent course. In cases with large MCA, biliary obstruction, pain from bowel compression, and exocrine or endocrine insufficiency have been observed. However, the vast majority of VHL patients with MCA remains asymptomatic, shows preservation of normal exocrine and endocrine pancreatic function, and doesn’t require surgery for many years despite radiological evidence of extensive pancreatic cystic disease.

Genotype/phenotype correlation has been reported in VHL disease. VHL type 1 phenotype (without pheochromocytoma) and VHL type 2 phenotype (with pheochromocytoma) have been described.28 The most frequent VHL mutation hot spot at the nucleotide 712/713 predisposes carriers to a VHL type 2 phenotype with a high risk of pheochromocytoma and RCC development.29 Concurrent central nervous system hemangioblastoma was present in all nine patients in the study (Table 1). Six patients had a concurrent retinal angioma, and six patients had a pheochromocytoma. Four of the nine patients had a concurrent pancreatic neuroendocrine tumor (NET). Eight VHL patients with pancreatic cystic disease had a germline mutation or partial deletion in exons 1 or 3 of the VHL gene. Four of the mutations resulted in frame shift and protein truncation, and five were missense mutations (Table 1). We did not observe a phenotype/genotype correlation in this study of nine VHL patients in whom pancreatic cystic tumors were discovered incidentally. A larger VHL population study of patients with pancreatic cystic disease would be necessary to investigate a phenotype/genotype correlation question further.

Differential diagnosis of pancreatic cystic neoplasia includes primary sporadic neoplasms of the pancreas such as mucinous cystadenoma, mucinous cystadenocarcinoma, adenocarcinoma, sugar tumor, and NET.30–33 Importantly, in VHL patients many lesions, ie, hemangioblastoma, retinal angioma, cystadenoma of the epidiymis, pancreatic NET, and RCC, demonstrate clear cell cytology and numerous small vessels. It is the histopathological similarity with both pancreatic NET and RCC metastases that may lead to misdiagnosis and, subsequently, to erroneous treatment of VHL patients. Both MCA and pancreatic NET contain cells that are cyto-keratin-positive, demonstrate cytoplasmic glycogen on PAS stain, and lack acidic mucin on mucicarmine stain. However, unlike NET, MCA is negative for S-100 and chromogranin A and lacks dense core granules and lipid globules on electron microscopic examination.33 MCA is a benign neoplasm in asymptomatic patients; pancreatic NET has a malignant potential to metastasize to the liver when it is 2 to 3 cm in size, and requires surgical excision.4

Figure 4. Representative results of LOH analysis at the VHL gene with a polymorphic marker D3S1110 in patients 1 and 2. Arrowheads show positions of both alleles. In patient 1, the upper allele is deleted in both BC and mMCA. In patient 2, the upper allele is deleted in 4 out of 6 mMCA, 2 out of 3 mMCA, and a BC as compared to normal pancreatic tissue. Endothelial cells that are closely intermixed with epithelial cells in pancreatic serous lesions are likely to contribute to contamination in LOH analysis data.
Histologically, pancreatic cysts and MCA are strikingly similar to renal cysts and clear cell RCC in VHL patients. Both pancreatic and renal lesions are cystic or solid in architecture, contain cytokeratin MAK6-positive, glycogen-rich epithelial cells, and have prominent small vessels. Unlike pancreatic MCA, clear cell RCC in VHL contains cytoplasmic lipids and demonstrates numerous red blood cells in cystic spaces. Renal cysts and RCC show fibrous pseudocapsule and may have stromal fibrosis. However, prominent stromal fibrosis and the presence of vimentin/SMAPositive smooth muscle cells are important features of pancreatic BC and MCA. Unlike benign MCA, VHL RCC has a known malignant potential. Although metastases of clear cell RCC to the pancreas have been reported in sporadic RCC cases, they are rare. In the setting of VHL disease, awareness of histopathological similarities between pancreatic MCA, NET, and RCC as well as other VHL lesions, and communication between a pathologist and clinician are of the utmost importance for the follow-up, prognosis, and treatment of patients.

In summary, our data provide morphological and molecular genetic evidence that VHL pancreatic cystic disease is a neoplastic process in that BC and mMCA arise at multiple foci in the pancreas, grow, and coalesce, forming MMCAs. Because multiple BC and MCA of the pancreas are caused by alteration of the VHL gene, they represent serous cyst-MCA continuum in the development of pancreatic serous neoplasia and should be considered an integral part of VHL disease.

References


